

Supplementary Table S1. Characteristics of the study population.

Variables	Mean ($\pm$ SD) or n (%)
Sociodemographic variables	
Age (years)	54.3 ($\pm$ 13.8)
Sex (female %)	130 (77.3%)
Race/ethnicity	
White	132 (78.6%)
Black	10 (8.3%)
Hispanic	9 (5.4%)
Asian or Pacific Islander	2 (1.2%)
American Indian or Alaskan Native	1 (0.6%)
Unknown	14 (8.3%)
Smoking (ever)	75 (44.6%)
IIM subtype	
DM	62 (36.9%)
PM/IMNM	59 (35.1%)
IBM	5 (2.9%)
OM	2 (1.2%)
ASYS	1 (0.6%)
Unspecified	39 (23.2%)
Time since symptoms onset (years)	8.5 ($\pm$ 7.5)
BMI	28.4 ($\pm$ 6.7)
Education (years)	14.1 ($\pm$ 2.2)
Total annual income (\$)	53229.16 ($\pm$ 31358.90)
Comorbidities	
Rheumatic disease comorbidity index	2.1 ($\pm$ 1.7)
Fibromyalgia	53 (31.5%)
Osteoarthritis	26 (15.5%)
Self-reported current depression	47 (27.9%)
Self-reported current anxiety	37 (22.0%)
Hypertension	84 (50.0%)
Myocardial infarction	6 (3.6%)
Diabetes mellitus	20 (11.9%)
Cancer	25 (14.9%)
Renal disease	16 (9.5%)
Pulmonary disorder	45 (26.8%)
GI disorder	82 (48.8%)
Cardiac condition	30 (17.9%)
Outcomes	
Health satisfaction (0-4)	2.1 ($\pm$ 1.4)
HAQ-II (0-3)	1.0 ($\pm$ 0.7)
PSD (0-31)	12.1 ($\pm$ 8.1)
Patient global disease activity (0-10)	3.8 ($\pm$ 2.8)
Pain VAS (0-10), mean (SD)	3.3 ($\pm$ 2.8)
Fatigue VAS (0-10), mean (SD)	4.6 ($\pm$ 3.2)
SF-36 PCS (0-100), mean (SD)	36.5 ($\pm$ 11.2)
SF-36 MCS (0-100), mean (SD)	47.0 ($\pm$ 12.0)
Medications	
NSAIDs	46 (27.4%)
Glucocorticoids	91 (54.2%)
DMARDs	139 (82.7%)
Biologics	14 (8.3%)